Archived: Aspirin for the Prevention of Cardiovascular Disease: Preventive Medication
Original Release Date: March 2009
This version of this topic is currently archived and inactive. It should be used for historical purposes only.
Archived: Recommendation Summary
Summary of Recommendations and Evidence
|Men, Age 45-79|
The USPSTF recommends the use of aspirin for men age 45 to 79 years when the potential benefit due to a reduction in myocardial infarctions outweighs the potential harm due to an increase in gastrointestinal hemorrhage. See the Clinical Considerations section for discussion of benefits and harms.
|Women, Age 55-79|
The USPSTF recommends the use of aspirin for women age 55 to 79 years when the potential benefit of a reduction in ischemic strokes outweighs the potential harm of an increase in gastrointestinal hemorrhage. See the Clinical Considerations section for discussion of benefits and harms.
|Men and Women, 80 Years and Older|
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of aspirin for cardiovascular disease prevention in men and women 80 years or older. See the Clinical Considerations section for suggestions for practice regarding the I statement.
|Women Younger than 55 (Stroke), Men Younger than 45 (MI)|
The USPSTF recommends against the use of aspirin for stroke prevention in women younger than 55 years and for myocardial infarction prevention in men younger than 45 years.
Go to the Clinical Considerations section for suggestions for practice when the evidence is insufficient.
Current as of: July 2019
Internet Citation: Final Update Summary: Aspirin for the Prevention of Cardiovascular Disease: Preventive Medication. U.S. Preventive Services Task Force. July 2019.